Influenza is an acute respiratory infectious disease characterized by high transmissibility, rapid spread, and year-round occurrence. Current surveillance data indicate that influenza incidence rates are elevated compared with historical baselines. Children—whose immune systems are still maturing—are particularly vulnerable to infection. When pediatric patients develop persistent coughing and fever due to influenza, caregivers often seek safe, evidence-based therapeutic options tailored to pediatric physiology.
Among available interventions, Kanglong Concentrated Pediatric Cough-Relieving Oral Liquid has emerged as a clinically supported option for managing influenza-associated respiratory symptoms in children. Formulated on the classical Traditional Chinese Medicine (TCM) prescription *Mahuang Xing Shi Gan Tang*, the product has been refined specifically for pediatric upper respiratory tract pathology. Its active components include ephedra (*Ephedra sinica*), which promotes lung dispersion and alleviates wheezing while counterbalancing heat; bitter apricot seed (*Prunus armeniaca*), which regulates lung qi and suppresses cough; and *Lonicera japonica* (honeysuckle) and *Isatis indigotica* (woad root), both of which exert antiviral, antibacterial, and heat-clearing effects. Together, these ingredients synergistically clear heat, disperse lung pathogens, resolve phlegm, and suppress cough.
Pharmacological studies confirm that ephedra contributes bronchodilatory and antitussive activity via smooth muscle relaxation, while bitter apricot seed demonstrates additional expectorant properties. Honeysuckle and woad root further enhance efficacy through broad-spectrum antiviral and anti-inflammatory mechanisms. Collectively, the formulation modulates antigen-driven immune responses, attenuates allergic and inflammatory cascades, and may support immune resilience during recovery—offering symptomatic relief and potentially accelerating clinical resolution.
Clinical validation comes from a multicenter trial published in the *Journal of Clinical Rational Drug Use*. In children diagnosed with acute upper respiratory tract infection manifesting as wind-heat pattern with phlegm retention, those treated with Kanglong Concentrated Pediatric Cough-Relieving Oral Liquid achieved significantly shorter time-to-fever resolution versus controls. Moreover, the intervention group showed higher symptom resolution rates—including cough, nasal congestion, purulent rhinorrhea, headache, aversion to wind, and pharyngeal erythema—and superior overall response rates based on both conventional and TCM diagnostic criteria. The study concluded that the oral liquid delivers robust efficacy and favorable safety in this pediatric population.
Dosing precision and formulation safety were also prioritized in development. Each 1.25 mL unit-dose vial accommodates age-stratified administration: distinct dosing regimens are specified for children under 2 years, aged 3–4 years, and aged 5–7 years—minimizing dosing errors and medication waste. Notably, the product replaces sucrose with steviol glycosides (a natural, non-caloric sweetener), preserving palatability while eliminating metabolic concerns associated with high sugar intake—a critical consideration in pediatric populations.
While Kanglong Concentrated Pediatric Cough-Relieving Oral Liquid offers a well-characterized, age-appropriate therapeutic option grounded in both traditional principles and modern clinical evidence, treatment decisions must always be made in consultation with a qualified healthcare provider. Caregivers should review the full prescribing information and adhere strictly to recommended indications, contraindications, and dosage guidelines to ensure optimal safety and outcomes.